Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237

1.

Large Differences in Small RNA Composition Between Human Biofluids.

Godoy PM, Bhakta NR, Barczak AJ, Cakmak H, Fisher S, MacKenzie TC, Patel T, Price RW, Smith JF, Woodruff PG, Erle DJ.

Cell Rep. 2018 Oct 30;25(5):1346-1358. doi: 10.1016/j.celrep.2018.10.014.

2.

Single-cell RNA sequencing reveals microglia-like cells in cerebrospinal fluid during virologically suppressed HIV.

Farhadian SF, Mehta SS, Zografou C, Robertson K, Price RW, Pappalardo J, Chiarella J, Hafler DA, Spudich SS.

JCI Insight. 2018 Sep 20;3(18). pii: 121718. doi: 10.1172/jci.insight.121718. [Epub ahead of print]

3.

Brain MRI Features of CSF Human Immunodeficiency Virus Escape.

Narvid J, Callen A, Talbott J, Uzelac A, Dupont SM, Chow F, Price RW, Rehani B.

J Neuroimaging. 2018 Nov;28(6):601-607. doi: 10.1111/jon.12552. Epub 2018 Aug 5.

PMID:
30079471
4.

Longitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary Human Immunodeficiency Virus Infection.

Sanford R, Ances BM, Meyerhoff DJ, Price RW, Fuchs D, Zetterberg H, Spudich S, Collins DL.

Clin Infect Dis. 2018 Nov 13;67(11):1697-1704. doi: 10.1093/cid/ciy362.

PMID:
29697762
5.

No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts.

Wright EJ, Grund B, Robertson KR, Cysique L, Brew BJ, Collins GL, Poehlman-Roediger M, Vjecha MJ, Penalva de Oliveira AC, Standridge B, Carey C, Avihingsanon A, Florence E, Lundgren JD, Arenas-Pinto A, Mueller NJ, Winston A, Nsubuga MS, Lal L, Price RW; INSIGHT START Neurology Substudy Group.

AIDS. 2018 May 15;32(8):985-997. doi: 10.1097/QAD.0000000000001778.

PMID:
29424786
6.

Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?

Burbelo PD, Price RW, Hagberg L, Hatano H, Spudich S, Deeks SG, Gisslén M.

J Infect Dis. 2018 Mar 13;217(7):1024-1032. doi: 10.1093/infdis/jix662.

7.

HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG.

PLoS Med. 2017 Nov 7;14(11):e1002417. doi: 10.1371/journal.pmed.1002417. eCollection 2017 Nov.

8.

Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls.

Yilmaz A, Blennow K, Hagberg L, Nilsson S, Price RW, Schouten J, Spudich S, Underwood J, Zetterberg H, Gisslén M.

Expert Rev Mol Diagn. 2017 Aug;17(8):761-770. doi: 10.1080/14737159.2017.1341313. Epub 2017 Jun 14. Review.

PMID:
28598205
9.

Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy.

Rahimy E, Li FY, Hagberg L, Fuchs D, Robertson K, Meyerhoff DJ, Zetterberg H, Price RW, Gisslén M, Spudich S.

J Infect Dis. 2017 Apr 1;215(7):1132-1140. doi: 10.1093/infdis/jix013.

10.

Greater Risk of Stroke of Undetermined Etiology in a Contemporary HIV-Infected Cohort Compared with Uninfected Individuals.

Chow FC, Price RW, Hsue PY, Kim AS.

J Stroke Cerebrovasc Dis. 2017 May;26(5):1154-1160. doi: 10.1016/j.jstrokecerebrovasdis.2017.02.010. Epub 2017 Mar 2.

11.

Relationship Between HIV Infection, Antiretroviral Therapy, Inflammatory Markers, and Cerebrovascular Endothelial Function Among Adults in Urban China.

Chow FC, Li Y, Hu Y, Chan J, Wang H, Xu W, Price RW, Sorond FA, Li T.

J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):339-346. doi: 10.1097/QAI.0000000000001254.

12.

Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV.

Anesten B, Yilmaz A, Hagberg L, Zetterberg H, Nilsson S, Brew BJ, Fuchs D, Price RW, Gisslén M.

Neurol Neuroimmunol Neuroinflamm. 2016 Nov 9;3(6):e300. eCollection 2016 Dec.

13.

Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA.

Joseph J, Cinque P, Colosi D, Dravid A, Ene L, Fox H, Gabuzda D, Gisslen M, Beth Joseph S, Letendre S, Mukerji SS, Nath A, Perez-Valero I, Persaud D, Price RW, Rao VR, Sacktor N, Swanstrom R, Winston A, Wojna V, Wright E, Spudich S.

J Virus Erad. 2016 Oct 5;2(4):243-250.

14.

No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau).

Krut JJ, Price RW, Zetterberg H, Fuchs D, Hagberg L, Yilmaz A, Cinque P, Nilsson S, Gisslén M.

Virulence. 2017 Jul 4;8(5):599-604. doi: 10.1080/21505594.2016.1212155. Epub 2016 Jul 19.

15.

Corrigendum to: "Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study" [EBioMedicine 3 (216) 135-140].

Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, Fuchs D, Spudich S, Blennow K, Zetterberg H.

EBioMedicine. 2016 May;7:287-288. doi: 10.1016/j.ebiom.2016.04.021. Epub 2016 Apr 20. No abstract available.

16.

Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment.

Edén A, Marcotte TD, Heaton RK, Nilsson S, Zetterberg H, Fuchs D, Franklin D, Price RW, Grant I, Letendre SL, Gisslén M.

PLoS One. 2016 Jun 13;11(6):e0157160. doi: 10.1371/journal.pone.0157160. eCollection 2016.

17.

Putamen volume and its clinical and neurological correlates in primary HIV infection.

Wright PW, Pyakurel A, Vaida FF, Price RW, Lee E, Peterson J, Fuchs D, Zetterberg H, Robertson KR, Walter R, Meyerhoff DJ, Spudich SS, Ances BM.

AIDS. 2016 Jul 17;30(11):1789-94. doi: 10.1097/QAD.0000000000001103.

18.

Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers.

Ganesh A, Lemongello D, Lee E, Peterson J, McLaughlin BE, Ferre AL, Gillespie GM, Fuchs D, Deeks SG, Hunt PW, Price RW, Spudich SS, Shacklett BL.

AIDS Res Hum Retroviruses. 2016 Aug;32(8):791-800. doi: 10.1089/AID.2015.0313. Epub 2016 May 2.

19.

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study.

Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, Fuchs D, Spudich S, Blennow K, Zetterberg H.

EBioMedicine. 2015 Nov 22;3:135-140. doi: 10.1016/j.ebiom.2015.11.036. eCollection 2016 Jan.

20.

Deep sequencing of HIV-1 variants from paired plasma and cerebrospinal fluid during primary HIV infection.

Gega A, Kozal MJ, Chiarella J, Lee E, Peterson J, Hecht FM, Liegler T, St John EP, Simen BB, Price RW, Spudich SS.

J Virus Erad. 2015;1(4):264-268.

21.

Cerebral vasoreactivity is impaired in treated, virally suppressed HIV-infected individuals.

Chow FC, Boscardin WJ, Mills C, Ko N, Carroll C, Price RW, Deeks S, Sorond FA, Hsue PY.

AIDS. 2016 Jan 2;30(1):45-55. doi: 10.1097/QAD.0000000000000875.

22.

Phenotypic Correlates of HIV-1 Macrophage Tropism.

Arrildt KT, LaBranche CC, Joseph SB, Dukhovlinova EN, Graham WD, Ping LH, Schnell G, Sturdevant CB, Kincer LP, Mallewa M, Heyderman RS, Rie AV, Cohen MS, Spudich S, Price RW, Montefiori DC, Swanstrom R.

J Virol. 2015 Nov;89(22):11294-311. doi: 10.1128/JVI.00946-15. Epub 2015 Sep 2.

23.

Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy.

Ferretti F, Gisslen M, Cinque P, Price RW.

Curr HIV/AIDS Rep. 2015 Jun;12(2):280-8. doi: 10.1007/s11904-015-0267-7. Review.

PMID:
25860317
24.

Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection.

Sturdevant CB, Joseph SB, Schnell G, Price RW, Swanstrom R, Spudich S.

PLoS Pathog. 2015 Mar 26;11(3):e1004720. doi: 10.1371/journal.ppat.1004720. eCollection 2015 Mar.

25.

Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Wright EJ, Grund B, Cysique LA, Robertson KR, Brew BJ, Collins G, Shlay JC, Winston A, Read TR, Price RW; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:97-108. doi: 10.1111/hiv.12238.

26.

Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.

Peterson J, Gisslen M, Zetterberg H, Fuchs D, Shacklett BL, Hagberg L, Yiannoutsos CT, Spudich SS, Price RW.

PLoS One. 2014 Dec 26;9(12):e116081. doi: 10.1371/journal.pone.0116081. eCollection 2014.

27.

Cerebral white matter integrity during primary HIV infection.

Wright PW, Vaida FF, Fernández RJ, Rutlin J, Price RW, Lee E, Peterson J, Fuchs D, Shimony JS, Robertson KR, Walter R, Meyerhoff DJ, Spudich S, Ances BM.

AIDS. 2015 Feb 20;29(4):433-42. doi: 10.1097/QAD.0000000000000560.

28.

Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection.

Suh J, Sinclair E, Peterson J, Lee E, Kyriakides TC, Li FY, Hagberg L, Fuchs D, Price RW, Gisslen M, Spudich S.

J Neuroinflammation. 2014 Dec 3;11:199. doi: 10.1186/s12974-014-0199-y.

29.

Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection.

Young AC, Yiannoutsos CT, Hegde M, Lee E, Peterson J, Walter R, Price RW, Meyerhoff DJ, Spudich S.

Neurology. 2014 Oct 28;83(18):1592-600. doi: 10.1212/WNL.0000000000000932. Epub 2014 Sep 26.

30.

Effect of CD4+ cell count and viral suppression on risk of ischemic stroke in HIV infection.

Chow FC, Bacchetti P, Kim AS, Price RW, Hsue PY.

AIDS. 2014 Nov 13;28(17):2573-7. doi: 10.1097/QAD.0000000000000452.

31.

Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.

Dahl V, Peterson J, Fuchs D, Gisslen M, Palmer S, Price RW.

AIDS. 2014 Sep 24;28(15):2251-8. doi: 10.1097/QAD.0000000000000400.

32.

Central nervous system HIV-1 infection.

Grill MF, Price RW.

Handb Clin Neurol. 2014;123:487-505. doi: 10.1016/B978-0-444-53488-0.00023-7. Review. No abstract available.

PMID:
25015501
33.

Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation.

Wang SX, Ho EL, Grill M, Lee E, Peterson J, Robertson K, Fuchs D, Sinclair E, Price RW, Spudich S.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):303-10. doi: 10.1097/QAI.0000000000000167.

34.

Evolving character of chronic central nervous system HIV infection.

Price RW, Spudich SS, Peterson J, Joseph S, Fuchs D, Zetterberg H, Gisslén M, Swanstrom R.

Semin Neurol. 2014 Feb;34(1):7-13. doi: 10.1055/s-0034-1372337. Epub 2014 Apr 8. Review.

35.

Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.

Jessen Krut J, Mellberg T, Price RW, Hagberg L, Fuchs D, Rosengren L, Nilsson S, Zetterberg H, Gisslén M.

PLoS One. 2014 Feb 11;9(2):e88591. doi: 10.1371/journal.pone.0088591. eCollection 2014.

36.

Longitudinal characterization of depression and mood states beginning in primary HIV infection.

Gold JA, Grill M, Peterson J, Pilcher C, Lee E, Hecht FM, Fuchs D, Yiannoutsos CT, Price RW, Robertson K, Spudich S.

AIDS Behav. 2014 Jun;18(6):1124-32. doi: 10.1007/s10461-013-0688-5.

PMID:
24385231
37.

An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy.

Dahl V, Gisslen M, Hagberg L, Peterson J, Shao W, Spudich S, Price RW, Palmer S.

J Infect Dis. 2014 May 15;209(10):1618-22. doi: 10.1093/infdis/jit805. Epub 2013 Dec 12.

38.
39.

Screening for HIV-associated peripheral neuropathy in resource-limited settings.

Cettomai D, Kwasa JK, Birbeck GL, Price RW, Cohen CR, Bukusi EA, Kendi C, Meyer AC.

Muscle Nerve. 2013 Oct;48(4):516-24. doi: 10.1002/mus.23795. Epub 2013 Aug 27.

40.

Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect.

Grund B, Wright EJ, Brew BJ, Price RW, Roediger MP, Bain MP, Hoy JF, Shlay JC, Vjecha MJ, Robertson KR; INSIGHT SMART Study Group.

J Neurovirol. 2013 Aug;19(4):383-92. doi: 10.1007/s13365-013-0190-x. Epub 2013 Aug 14.

41.

Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection.

Price RW, Peterson J, Fuchs D, Angel TE, Zetterberg H, Hagberg L, Spudich S, Smith RD, Jacobs JM, Brown JN, Gisslen M.

J Neuroimmune Pharmacol. 2013 Dec;8(5):1147-58. doi: 10.1007/s11481-013-9491-3. Epub 2013 Aug 13. Review.

42.

Cellular Composition of Cerebrospinal Fluid in HIV-1 Infected and Uninfected Subjects.

Ho EL, Ronquillo R, Altmeppen H, Spudich SS, Price RW, Sinclair E.

PLoS One. 2013 Jun 18;8(6):e66188. doi: 10.1371/journal.pone.0066188. Print 2013.

43.

Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.

Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, Eisele E, Haase A, Ho YC, Hütter G, Justement JS, Keating S, Lee TH, Li P, Murray D, Palmer S, Pilcher C, Pillai S, Price RW, Rothenberger M, Schacker T, Siliciano J, Siliciano R, Sinclair E, Strain M, Wong J, Richman D, Deeks SG.

PLoS Pathog. 2013;9(5):e1003347. doi: 10.1371/journal.ppat.1003347. Epub 2013 May 9.

44.

Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy.

Yilmaz A, Yiannoutsos CT, Fuchs D, Price RW, Crozier K, Hagberg L, Spudich S, Gisslén M.

J Neuroinflammation. 2013 May 10;10:62. doi: 10.1186/1742-2094-10-62.

45.

Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection.

Peluso MJ, Meyerhoff DJ, Price RW, Peterson J, Lee E, Young AC, Walter R, Fuchs D, Brew BJ, Cinque P, Robertson K, Hagberg L, Zetterberg H, Gisslén M, Spudich S.

J Infect Dis. 2013 Jun 1;207(11):1703-12. doi: 10.1093/infdis/jit088. Epub 2013 Mar 4.

46.

Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers.

Dahl V, Peterson J, Spudich S, Lee E, Shacklett BL, Price RW, Palmer S.

AIDS. 2013 Apr 24;27(7):1145-9. doi: 10.1097/QAD.0b013e32835cf235.

47.

Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections.

Krut JJ, Zetterberg H, Blennow K, Cinque P, Hagberg L, Price RW, Studahl M, Gisslén M.

J Neurol. 2013 Feb;260(2):620-6. doi: 10.1007/s00415-012-6688-y. Epub 2012 Oct 9.

PMID:
23052602
48.

Targeting chronic central nervous system HIV infection.

Price RW, Swanstrom R.

Antivir Ther. 2012;17(7):1227-31. doi: 10.3851/IMP2414. Epub 2012 Sep 28.

PMID:
23018178
49.

Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration.

Fanara P, Wong PY, Husted KH, Liu S, Liu VM, Kohlstaedt LA, Riiff T, Protasio JC, Boban D, Killion S, Killian M, Epling L, Sinclair E, Peterson J, Price RW, Cabin DE, Nussbaum RL, Brühmann J, Brandt R, Christine CW, Aminoff MJ, Hellerstein MK.

J Clin Invest. 2012 Sep;122(9):3159-69. doi: 10.1172/JCI64575. Epub 2012 Aug 27.

50.

Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.

Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, Gisslén M, Angoff N, Price RW, Cinque P, Spudich S.

AIDS. 2012 Sep 10;26(14):1765-74. doi: 10.1097/QAD.0b013e328355e6b2.

Supplemental Content

Loading ...
Support Center